COVID-19 Vaccine Market set for steady growth to US$ 29.98 billion by 2033, growing at a CAGR of 9.8%, led by North America 38% global market share.

The Global COVID-19 Vaccine Market reached US$ 13.43 billion in 2024 and is expected to reach US$ 29.98 billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033, according to DataM Intelligence research.

Market growth is driven by the ongoing need for booster vaccination programs, increasing focus on variant-specific and next-generation vaccines, and rising awareness of pandemic preparedness and immunization initiatives. Additionally, strong government vaccination strategies, expanding vaccine manufacturing capabilities, advancements in mRNA and recombinant vaccine technologies, and increasing vaccination efforts in emerging economies are further supporting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/covid-19-vaccine-market?pratik

United States: Key Industry Developments
✅ December 2025: Moderna introduced mNEXSPIKE, a next-generation COVID-19 vaccine targeting older adults and high-risk groups with lower antigen doses for improved safety and efficacy against variants.
​
✅ July 2025: Sanofi acquired Vicebio for USD 1.15 billion to bolster its respiratory vaccine pipeline, including advancements in COVID-19 combination vaccines amid shifting booster demands.
​
✅ June 2025: Pfizer reaffirmed its 2025 revenue guidance, projecting sustained COVID-19 product sales while expanding manufacturing for variant-adapted boosters to support annual vaccination programs.
​
Asia Pacific / Japan: Key Industry Developments
✅ November 2025: Japanese regulators expanded approvals for next-gen mRNA COVID-19 boosters from Pfizer and Moderna, integrating them into national protocols for high-risk populations amid seasonal variant surges.
​
✅ October 2025: Takeda Pharmaceutical partnered with global firms on localized production of Novavax protein-based COVID-19 vaccines, enhancing supply chain resilience and accessibility in Japan.
​
✅ September 2025: Japan's Ministry of Health approved subsidies for annual COVID-19 vaccinations, promoting uptake of updated formulations to address waning immunity and emerging strains.

Key Merges and Acquisitions(2025):
BioNTech - acquired CureVac on December 18, 2025, solidifying its leadership in the mRNA technology segment of the COVID-19 vaccine market through the integration of CureVac's proprietary mRNA design, advanced Lipid Nanoparticle formulations, and RNA Printer platform for scalable production, while resolving ongoing patent disputes and enhancing its oncology pipeline alongside COVID-related assets.

Market Segmentation Analysis:
By Technology Platform
mRNA vaccines dominate with 54.7% market share in 2024-2025, driven by Pfizer-BioNTech and Moderna's rapid variant adaptation and high efficacy against strains like Omicron.
Viral vector vaccines, such as AstraZeneca's, hold a significant portion due to established production scales, while protein subunit vaccines like Novavax gain through partnerships.
Inactivated vaccines (e.g., Sinovac, Sinopharm) and others like DNA platforms capture the rest, prominent in Asia for cost-effective mass immunization.
​
By Valency
Bivalent formulations lead with 61.2% of global volume in 2024, preferred for dual-strain coverage balancing broad protection and manufacturability.
Monovalent original-strain doses are phasing out in major markets like Europe and North America, limited to aid channels.
Polyvalent/multivalent and pan-coronavirus candidates are emerging, supported by R&D for future variants.
​
By End-User
Government immunization programs hold the largest share, fueled by public procurement and national rollout mandates.
Hospitals and clinics follow, focusing on high-risk populations and booster campaigns.
​Other channels like private clinics gain from telehealth but remain secondary.

Purchase this report before year-end and unlock an exclusive 30% discount:https://www.datamintelligence.com/buy-now-page?report=covid-19-vaccine-market?pratik (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
1️⃣ Continued emergence of new variants
Ongoing viral mutations (Omicron sub-lineages and future strains) are sustaining demand for updated booster vaccines.
Need for variant-specific and multivalent formulations supports recurring immunization programs.

2️⃣ Government vaccination programs & policy support
National immunization strategies, preparedness frameworks, and pandemic response reserves.
Ongoing procurement agreements, especially in North America, Europe, and parts of Asia.

3️⃣ Rising focus on booster and seasonal vaccination
Shift from emergency vaccination to routine/seasonal boosters similar to influenza vaccination norms.
Increasing recommendations for elderly, immunocompromised, and healthcare workers.

4️⃣ Growing awareness and vaccination infrastructure
Improved distribution networks, cold chain development, and broader health awareness.
Strengthening public-private partnerships and better healthcare accessibility in developing regions.

5️⃣ Technological advancements in vaccine platforms
mRNA, protein-subunit, vector, and next-gen vaccines offering improved protection, stability, and faster adaptation.
Research in pan-coronavirus vaccines driving innovation.

Regional Insights:
North America commands the largest share of the COVID-19 vaccine market, estimated at around 38% in recent assessments, driven by advanced healthcare infrastructure, high vaccination rates, substantial government investments, and strong public health systems in the US and Canada.
​
Europe follows as the second-largest region, benefiting from robust regulatory frameworks, widespread booster programs in countries like Germany, the UK, and France, and established pharmaceutical manufacturing, though shares fluctuate with variant-driven demand.
​
Asia Pacific ranks third in market share, yet exhibits the fastest growth potential with high CAGRs in nations such as China, India, and Japan, fueled by massive population coverage, local production hubs like Sinovac and Serum Institute, and expanding immunization initiatives.

Speak to Our Analyst and Get Customization in the report as per your requirements:https://www.datamintelligence.com/customize/covid-19-vaccine-market?pratik

Key Players:
Pfizer/BioNTech, Moderna, Inc., AstraZeneca., Johnson & Johnson (Janssen Scientific Affairs, LLC), SINOVAC, CanSino Biologics Inc., Novavax., Sanofi/GSK, Beijing Institute of Biological Products Co., Ltd., Serum Institute of India Pvt. Ltd., and Gamaleya Research Institute among others.

Key Highlights (Top 5 Key Players) :
Pfizer/BioNTech
Pfizer partnered with BioNTech to develop the pioneering mRNA COVID-19 vaccine Comirnaty, achieving full FDA approval and leading global distribution through robust manufacturing and variant adaptations.

Moderna
Moderna pioneered mRNA technology with its Spikevax vaccine, scaling production rapidly for emergency authorizations worldwide and updating formulas for emerging variants efficiently.
​
AstraZeneca
AstraZeneca collaborated with Oxford University on a viral vector vaccine, emphasizing equitable access via technology transfers and production in low-income regions for broad immunization.

Johnson & Johnson (Janssen)
Johnson & Johnson's single-dose adenovirus vaccine simplified logistics for resource-limited areas, focusing on safety monitoring and variant research for reliable public health impact.
​
Novavax
Novavax developed a protein subunit vaccine with strong immune responses, prioritizing scalable production and storage to support diverse global dosing strategies.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?pratik

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.